Pancreatic Cancer Serum Biomarker PC-594: Diagnostic Performance and Comparison to CA19-9

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Jun 16

PMID 26074698

Citations 11

Authors

Shawn A Ritchie

Bassirou Chitou

Qingan Zheng

Dushmanthi Jayasinghe

Wei Jin

Asuka Mochizuki

Dayan B Goodenowe

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate serum PC-594 fatty acid levels as a potential biomarker in North American pancreatic cancer (PaC) patients, and to compare its performance to CA19-9.

Methods: Using tandem mass spectrometry, we evaluated serum PC-594 levels from 84 North American patients with confirmed PaC and 99 cancer-free control subjects. We determined CA19-9 levels by ELISA. Significance between PaC patients and controls, and association with clinical variables was determined by analysis of variance and t-tests. Diagnostic performance was evaluated by receiver-operator characteristic (ROC) curve analysis, and PC-594 correlation with age and CA19-9 determined by regression analysis.

Results: Mean PC-594 levels were 3.7 times lower in PaC patients compared to controls (P < 0.0001). The mean level in PaC patient serum was 0.76 ± 0.07 μmol/L, and the mean level in control subjects was 2.79 ± 0.15 μmol/L. There was no correlation between PC-594 and age, disease stage or gender (P > 0.05). Using 1.25 μmol/L as a PC-594 threshold produced a relative risk (RR) of 9.4 (P < 0.0001, 95%CI: 5.0-17.7). The area under the receiver-operator characteristic curve (ROC-AUC) was 0.93 (95%CI: 0.91-0.95) for PC-594 and 0.85 (95%CI: 0.82-0.88) for CA19-9. Sensitivity at 90% specificity was 87% for PC-594 and 71% for CA19-9. Six PaC patients with CA19-9 above 35 U/mL showed normal PC-594 levels, while 24 PaC patients with normal CA19-9 showed low PC-594 levels. Eighty-five of the 99 control subjects (86%) showed normal levels of both markers.

Conclusion: PC-594 biomarker levels are significantly reduced in North American PaC patients, and showed superior diagnostic performance compared to CA19-9.

Citing Articles

Advancements in Early Detection and Screening Strategies for Pancreatic Cancer: From Genetic Susceptibility to Novel Biomarkers.

Shah Y, Dahiya D, Tiwari A, Kumar H, Gangwani M, Ali H J Clin Med. 2024; 13(16).

PMID: 39200847 PMC: 11355237. DOI: 10.3390/jcm13164706.

Earlier Diagnosis of Pancreatic Cancer: Is It Possible?.

Koltai T Cancers (Basel). 2023; 15(18).

PMID: 37760400 PMC: 10526520. DOI: 10.3390/cancers15184430.

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review.

Calanzani N, Druce P, Snudden C, Milley K, Boscott R, Behiyat D Adv Ther. 2020; 38(2):793-834.

PMID: 33306189 PMC: 7889689. DOI: 10.1007/s12325-020-01571-z.

Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma.

Rho S, Lee S, Park M, Lee J, Lee S, Hwang H Sci Rep. 2019; 9(1):18634.

PMID: 31819109 PMC: 6901525. DOI: 10.1038/s41598-019-55016-x.

Endogenous Anti-Inflammatory Very-Long-Chain Dicarboxylic Acids: Potential Chemopreventive Lipids.

Wood P Metabolites. 2018; 8(4).

PMID: 30400281 PMC: 6315409. DOI: 10.3390/metabo8040076.

References

Permuth-Wey J, Egan K . Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2008; 8(2):109-17. DOI: 10.1007/s10689-008-9214-8. View

Helmstaedter L, Riemann J . Pancreatic cancer--EUS and early diagnosis. Langenbecks Arch Surg. 2008; 393(6):923-7. DOI: 10.1007/s00423-007-0275-1. View

Lee E, Lee J . Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014; 20(24):7864-77. PMC: 4069314. DOI: 10.3748/wjg.v20.i24.7864. View

Becker A, Hernandez Y, Frucht H, Lucas A . Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014; 20(32):11182-98. PMC: 4145757. DOI: 10.3748/wjg.v20.i32.11182. View

Ritchie S, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H . Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013; 13:416. PMC: 3847543. DOI: 10.1186/1471-2407-13-416. View

Ballehaninna U, Chamberlain R . The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012; 3(2):105-19. PMC: 3397644. DOI: 10.3978/j.issn.2078-6891.2011.021. View

ONeill E, Hammond N, Miller F . MR imaging of the pancreas. Radiol Clin North Am. 2014; 52(4):757-77. DOI: 10.1016/j.rcl.2014.02.006. View

Takeshita K, Kutomi K, Haruyama T, Watanabe A, Furui S, Fukushima J . Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol. 2010; 83(994):823-30. PMC: 3473757. DOI: 10.1259/bjr/80905803. View

Bilimoria K, Bentrem D, Ko C, Ritchey J, Stewart A, Winchester D . Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110(4):738-44. DOI: 10.1002/cncr.22852. View

10.

Bournet B, Gayral M, Torrisani J, Selves J, Cordelier P, Buscail L . Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterol. 2014; 20(31):10758-68. PMC: 4138456. DOI: 10.3748/wjg.v20.i31.10758. View

11.

Sharma C, Eltawil K, Renfrew P, Walsh M, Molinari M . Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol. 2011; 17(7):867-97. PMC: 3051138. DOI: 10.3748/wjg.v17.i7.867. View

12.

Yao X, Zeng M, Wang H, Fei S, Rao S, Ji Y . Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results. Radiol Med. 2011; 117(5):780-8. DOI: 10.1007/s11547-011-0757-7. View

13.

Fan Z, Li Y, Yan K, Wu W, Yin S, Yang W . Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions--a comparison of conventional ultrasound and contrast-enhanced CT. Eur J Radiol. 2013; 82(9):1385-90. DOI: 10.1016/j.ejrad.2013.04.016. View

14.

Yao X, Kuang T, Wu L, Feng H, Liu H, Cheng W . Optimization of MR diffusion-weighted imaging acquisitions for pancreatic cancer at 3.0T. Magn Reson Imaging. 2014; 32(7):875-9. DOI: 10.1016/j.mri.2014.04.011. View

15.

Dimcevski G, Erchinger F, Havre R, Gilja O . Ultrasonography in diagnosing chronic pancreatitis: new aspects. World J Gastroenterol. 2013; 19(42):7247-57. PMC: 3831206. DOI: 10.3748/wjg.v19.i42.7247. View

16.

Kau S, Shyr Y, Su C, Wu C, Lui W . Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999; 188(4):415-20. DOI: 10.1016/s1072-7515(98)00326-3. View

17.

Flook R, Veldhuyzen Van Zanten S . Pancreatic cancer in Canada: incidence and mortality trends from 1992 to 2005. Can J Gastroenterol. 2009; 23(8):546-50. PMC: 2732175. DOI: 10.1155/2009/986531. View

18.

Humphris J, Chang D, Johns A, Scarlett C, Pajic M, Jones M . The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012; 23(7):1713-22. PMC: 3387824. DOI: 10.1093/annonc/mdr561. View

19.

Ritchie S, Jayasinghe D, Davies G, Ahiahonu P, Ma H, Goodenowe D . Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res. 2011; 30:59. PMC: 3108922. DOI: 10.1186/1756-9966-30-59. View

20.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View